Erratum: The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-005-9031-9);The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer

Breast Cancer Research and Treatment

Volumn 96, Issue 3, 2006, Pages 203-206

  Gainford, M C ^a   McCready, D ^b   Cohen, Z ^b   Clemons, M ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Aromatase inhibitors; Breast cancer; Medical education

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MEDICAL EDUCATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SURGEON;

EID: 33645718701     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9165-4     Document Type: Erratum

References (13)

1. Clemons MJ, Goss PE: Estrogen exposure and breast cancer risk. N Eng J Med 344(4): 276-285, 2001
2. Clarke M, Collins R, Darby S, et al.: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet 9472: 1687-1717, 2005
3. Nabholtz JM, Buzdar A, Pollak M, et al.: Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767, 2000
4. Bonneterre J, Thurlimann B, Robertson JF, et al.: Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18: 3748-3757, 2000
5. Mouridsen H, Sun Y, Gershanovich M, et al.: Final survival analysis of the double blind, randomized, multinational phase III trial of letrozole compared to tamoxifen as first line hormonal therapy for advanced breast cancer. Breast Cancer Res Treat 69: 211, 2001
6. Coombes C, Hall E, Gibson L, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092, 2004
7. Goss P, Ingle J, Martino S, et al.: A randomized trial of letrozole in post - menopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349: 1793-1802, 2003
8. Howell A: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005
9. Jakesz R, Kaufmann M, Gnant M, et al.: Benefits of switching postmenopausal women with hormone sensitive early breast cancer to anastrazole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88: Abstract 2, 2004
10. BIG 1-98 Collaborative Group. Letrozole vs Tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer, BIG 1-98: A prospective randomized double blind phase III study. Breast 2005; 14: S4
11. Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor positive breast cancer: Status reports 2004. J Clin Oncol 2005, epub ahead of print 10.1200/JCO.2005.09. 121
12. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19(3): 881-894, 2001
13. Clemons M, Coleman RE, Verma S: Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 30(4): 325-332, 2004